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Abstract
MicroRNAs are small ~22nt single stranded RNAs that negatively regulate protein expression by 
binding to partially complementary sequences in the 3′UTRs of target gene mRNAs. Recently, 
mutations have been identified in both microRNAs and target genes that disrupt regulatory 
relationships, contribute to oncogenesis and serve as biomarkers for cancer risk. KIT, an 
established oncogene with a multifaceted role in melanogenesis and melanoma pathogenesis, has 
recently been shown to be up-regulated in some melanomas, and is also a target of the microRNA 
miR-221. Here we describe a genetic variant in the 3′UTR of the KIT oncogene that correlates 
with a greater than fourfold increased risk of acral melanoma. This KIT variant results in a 
mismatch in the seed region of a miR-221 complementary site and reporter data suggests that this 
mismatch can result in increased expression of the KIT oncogene. Consistent with the hypothesis 
that this is a functional variant, KIT mRNA and protein levels are both increased in the majority of 
samples harboring the KIT variant. This work identifies a novel genetic marker for increased 
heritable risk of melanoma.
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Introduction
Melanoma, a malignancy that arises from melanocytes (most often of the skin), is one of the 
least common but most fatal forms of skin cancer, representing only 3% of skin cancers but 
resulting in over 75% of skin cancer deaths. An estimated 69 000 cases of melanoma were 
diagnosed in the U.S. in 2009 and the incidence of this cancer is increasing (Rigel). 
Melanoma is treatable if caught at the early, localized stage, with a five-year survival rate of 
99%. However, this survival rate drops to just 29% for patients diagnosed with a more 
advanced stage, such as an ulcerated tumor with lymph node involvement, highlighting the 
importance of early detection and risk assessment (Gershenwald et al.). Approximately 10% 
of all melanoma cases are thought to be hereditary. For example, family linkage studies 
identified an autosomal-dominant, melanoma gene located on chromosome 9p21.4. This 
gene, called CDKN2A (also known as p16 or INK4A or MTS1), accounts for up to 40% of 
these hereditary melanoma cases (Meyle & Guldberg, 2009). However, other genetic 
mutations accounting for inherited melanoma risk are unknown.
MicroRNAs (miRNAs) are small ~22nt single-stranded RNAs that negatively regulate 
protein expression by partially complementary binding usually to the 3′ untranslated region 
(UTR) of mRNAs of target genes. MiRNAs have been demonstrated to have significant 
roles in a wide range of cellular processes including development, aging, immunity and 
disease. In particular, miRNAs have been identified as key players in a virtually all cancers 
studied, acting as both tumor suppressors and oncogenes (Medina & Slack, 2008; Stefani, 
2007). Sequence conservation of miRNAs across species is strong, as is conservation of 
miRNA binding sites in the 3′UTRs of target genes (Lee et al., 2007).
A key regulator of melanocyte development, the KIT oncogene, has recently been identified 
as a target of miR-221 in melanoma (Felicetti et al., 2008; Igoucheva & Alexeev, 2009). 
KIT is a receptor tyrosine kinase (RTK) that binds the ligand Stem-Cell Factor (SCF), also 
known as mast cell growth factor and steel factor (SF) (Smalley et al., 2009b). KIT 
activation drives a number of downstream pathways associated with malignant 
transformation, including the PI3K/AKT pathway, known to be important for melanoma 
progression, as well as the JAK/STAT and MAPK pathways (Smalley et al., 2009b). It is 
therefore not surprising that aberrant KIT expression and signaling has been described in 
multiple cancers (Went et al., 2004). For example, KIT expression is particularly robust in 
gastrointestinal stromal tumors (GISTs), for which immmunohistochemical detection of KIT 
positivity is considered a prerequisite for diagnosis, and treatment of this type of cancer has 
seen significant success with the KIT-inhibitor Imatinib (Demetri et al., 2002). However, the 
role of KIT in melanoma appears complex. KIT, which in some studies seems a promising 
candidate oncogene in melanoma, has in earlier work been shown to have decreased 
expression in large number of cutaneous melanomas relative to primary melanocytes 
(Funasaka et al., 1992; Lassam & Bickford, 1992; Natali et al., 1992; Went et al., 2004), and 
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in some studies either exogenous re-expression of the receptor, or addition of the ligand to 
the culture medium of KIT-expressing melanoma cells, can inhibit growth in cell culture 
(Huang et al., 1998; Huang et al., 1996; Zakut et al., 1993). Conversely, recent studies have 
shown positive KIT expression in 36% of melanomas examined (Went et al., 2004), and 
have demonstrated KIT signaling as the driving oncogenic event in some sub-groups of 
melanoma, which harbor activating mutations or amplifications of KIT (Curtin et al., 2006; 
Smalley et al., 2009a; Smalley et al., 2009b). In particular, KIT expression appears to be 
associated with acral melanoma (Ashida et al., 2009; Curtin et al., 2006), which occurs on 
the distal parts of the body and mucosal surfaces. Activating mutations or amplifications of 
KIT have been found in 39% of mucosal and 36% of acral melanomas (Curtin et al., 2006). 
While previous trials using Imatinib to treat melanoma were negative, a body of recent work 
suggests that this drug and similar RTK inhibitors may have promise with respect to this 
class of KIT-driven cancers (Ashida et al., 2009; Jiang et al., 2008).
Recent work from several laboratories has examined the effects of mutations in miRNAs 
and their targets, and have identified genetic markers of cancer risk (Mishra & Bertino, 
2009). For example, a single-nucleotide polymorphism (SNP) in the miR-146a precursor 
results in production of polymorphic pre-miRNAs from the passenger strand and 
predisposes to papillary thyroid carcinoma (Jazdzewski et al., 2009). A SNP in the 
miR-125b binding site in the BMPR1B 3′UTR disrupts miRNA repression of this target and 
confers increased risk of breast cancer (Saetrom et al., 2009). We found that a SNP in a let-7 
miRNA complementary site in the 3′UTR of the KRAS oncogene disrupted base-pairing in 
the miRNA:target duplex and significantly increased risk of non-small cell lung cancer 
(NSCLC) (Chin et al., 2008) and ovarian cancer (Ratner et al., 2010). Given these examples, 
we speculated that 3′UTR variants might play roles in the development and pathogenesis of 
melanoma.
Here we show that a genetic variation in a miR-221 complementary site in the KIT 3′UTR 
correlates with increased risk of melanoma, specifically of the acral subtype, and propose 
this variant allele as a new genetic marker for acral melanoma risk.
Results
A variant allele in a miR-221 complementary site in the KIT 3′UTR
We amplified the 3′UTR of the KIT oncogene from genomic DNA of 70 melanoma patients, 
and examined this region for sequence variability. As all but one of available melanoma 
samples were taken from patients of European descent, the study was limited to this group. 
We found a high frequency of heterozygosity for a variant/derived “A” allele at rs17084733 
(3169G→A) (24.3%) in our samples relative to 16.7 to 23.3% in various European 
(“Caucasian”) samples as reported in dbSNP (Sayers et al., 2009; Sherry et al., 2001). The 
KIT 3′UTR has been validated as a target of miR-221 by reporter assays (Felicetti et al., 
2008; Igoucheva & Alexeev, 2009), and three binding sites have been proposed based on 
computational prediction software. The variant allele at rs17084733 (referred to here as the 
KIT variant) is predicted to disrupt base pairing within the seed region of the 5′-most 
miR-221 complementary site (He et al., 2005) (Fig. 1A). Interestingly, the KIT variant was 
previously reported in a study examining the correlation between high miR-221 and low 
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KIT expression in papillary thyroid carcinoma (He et al., 2005). Out of 10 patients with low 
levels of KIT protein and gene transcript, five were heterozygous at rs17084733, an 
observation that conflicts with the hypothesis that this KIT variant would result in increased 
expression of KIT. Significantly, this miR-221 complementary site is highly conserved in 
mammals, with the site of rs17084733 being most conserved, and with the least conserved 
base lying at a site not predicted to base-pair in the miR-221:target duplex (Fig. 1B).
The frequency of the variant allele in worldwide populations
As reported above, rs17084733 is a locus with low frequency of heterozygosity in the 
dbSNP and HapMap databases. To verify that the frequency of the rs17084733 variant in 
melanoma exceeded that of the general population and may therefore be a marker of 
melanoma risk, we examined the genotype of this locus in 2,765 healthy individuals from 58 
groups around the world representing African, Southwest Asian, European, Siberian, Central 
Asian, Pacific Islander, East Asian, North American, and South American populations from 
a Yale collection (Rajeevan et al. 2005). We found a large range of frequency of the variant 
allele, spanning from 0% in all South American groups as well as sub-groups from four 
other populations, to 43.2% in the Papua New Guinea sub-group of the Pacific Islanders 
(Fig. 2). Range was variable across groups, including Europeans, which had and average 
frequency of the variant allele of 10.0%, but a range from 1.5% in Finns to 22.9% in 
Sardinians. European Americans in this panel had an allelic frequency of 10.3%. Our 
melanoma samples had an allelic frequency of 12.9%, representing a 29.0% and 25.2% 
increase in frequency of this allele relative the European average and European Americans 
respectively. However, given the range of frequencies observed, we concluded that a control 
population closely representative of the population from which the melanoma samples were 
gathered was required. Note that above, we are reporting allelic frequency rather than 
frequency of heterozygosity to account for rare homozygotes for this KIT variant in large 
worldwide populations.
Case-control analysis of the KIT variant in melanoma demonstrates increased melanoma 
risk in carriers of the variant allele
As all of our melanoma patients were taken from a Yale/New Haven Hospital patient cohort, 
we assembled a control for our specific study panel taken from healthy individuals from the 
same community (Supplementary Table 1). We found a frequency of heterozygosity of the 
variant allele to be 16.0% (n=94) in this population, whereas the frequency of heterozygosity 
in melanoma patients is 24.6% (n=69), demonstrating a statistically significant 53.8% 
increase in the frequency of heterozygosity for this allele in patients with melanoma 
(p=0.02) (Fig. 3). The odds ratio (OR) for the frequency of heterozygosity in melanoma 
patients relative to controls, adjusted for gender and age, is 3.30 (95% CI (1.27, 8.86)) 
indicating that the presence of this KIT variant more than triples the risk for melanoma. 
Taken together these data indicate that this KIT variant may be a strong predictive marker 
for increased risk of melanoma.
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The presence of the variant allele correlates specifically with increased risk of acral 
melanoma
As recent work has indicated that KIT expression is associated with acral melanomas, we 
had included several tumors of this subtype in our initial patient pool. To determine whether 
this variant is particularly associated with acral melanoma we compared the frequency of 
heterozygosity of the KIT variant in acral and non-acral subtypes (Supplementary Table 1). 
We found the frequency of heterozygosity of the KIT variant in non-acral samples to be 
22.0% (n=41), demonstrating a 38% increase relative to controls; however this difference is 
not statistically significant (p=0.070). In contrast, the frequency of heterozygosity in the 
acral subtype was 28.6% (n=28), demonstrating a 78.8% increase in the frequency of 
heterozygosity of this KIT variant in these cancers relative to controls, with an OR of 4.24 
(95% CI (1.25, 14.65) p=0.02), indicating that this KIT variant may be a strong marker 
specifically for risk of acral melanoma (Fig. 3).
KIT mRNA and protein in samples harboring the variant allele
To determine the impact of the variant on KIT expression we examined whether the 
presence of the variant allele correlated with altered levels of KIT mRNA and protein levels 
in melanoma. Microarray gene expression analyses revealed significantly higher levels of 
KIT mRNA in samples heterozygous for the variant allele relative to wild-type samples 
(Fig. 4). While sample numbers were low for these experiments, the maginitude of the 
difference in expression levels far overcomes the sample size. Similarly, Western blots 
analyses showed that 60% of samples heterozygous for the KIT variant allele were positive 
for KIT expression, compared to only 24% of wild-type samples, suggesting that the 
presence of the KIT variant may result in increased expression of KIT protein. However 
given the binary nature of either positive or negative KIT expression and sample size we 
present this as a correlation rather than a statistically significant difference (Fig. 5). We also 
found that the expression of miR-221 was slightly higher in patients carrying the variant 
allele, (Suppl. Fig. 2, Suppl. Table 2), however this difference was not statistically 
significant. Additionally, miR-221 expression was not decreased in the KIT positive samples 
relative to the KIT negative samples in either the wild-type or variant group suggesting that 
the increase in KIT expression in the variant relative to the wild-type group is not merely 
due to a decrease in expression of miR-221 (Suppl. Fig. 3).
Reporter assays indicate that the variant allele disrupts KIT 3′UTR mediated translational 
repression
To determine how the variant allele affects KIT expression in vitro, we designed two 
constructs in which the 3′UTR of KIT was cloned into a Renilla luciferase reporter, with and 
without the KIT variant. These constructs were transfected into the 501 mel melanoma cell 
line, which expresses miR-221 (1.7-fold increase in expression relative to average of 
melanoma samples tested, (Suppl. Table 2)), and assayed for luciferase activity. The studies 
demonstrated a 6.7-fold increase in luciferase activity in the presence of the variant allele 
relative to the wild-type allele (normalized to internal vector Firefly luciferase control, p = 
0.0233) (Fig. 6a). To test if this derepression depended on miR-221 and the 5′ miR-221 
complemntary site, we knocked-out both the 3′ miR-221 complementary sites in the KIT 
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3′UTR within the above vectors and co-transfected them into the YUSAC2 melanoma cell 
line along with exogenous miR-221 pre-miR. These studies demonstrated a 1.24-fold 
increase in luciferase activity in the presence of the variant allele relative to the wildtype 
allele with downstream miR-221 binding sites knocked out (normalized to scrambled pre-
miR control and internal Firefly luciferase control, p = 0.0389) (Fig. 6b). Thus, the variant 
allele causes derepression of the KIT 3′UTR in vitro and may allow increased KIT 
expression in vivo.
The variant allele is not linked to known KIT activating mutations
KIT activating mutations have been identified in exons 11, 13 and 17 of the coding region. 
To determine if the variant at rs17084733 might be merely a bystander linked to one of 
these mutations, these exons were sequenced in 10 samples carrying the variant allele. No 
mutations were found.
The variant allele is a germline mutation
As rs17084733 has been previously reported as a human SNP, it strongly suggests that this 
SNP is a germline variant, and not a somatic mutation. To test this hypothesis we obtained 
paired normal lymphocytes for 11 of our melanoma samples carrying rs17084733. Of these 
10 (91%), also carried this KIT variant, strongly supporting the hypothesis that this is 
overwhelmingly a germline variant, and thus a potential genetic marker for melanoma risk.
Discussion
Here we demonstrate that a variant in the seed region of a miR-221 complementary site in 
the 3′UTR of the KIT mRNA correlates with a greater than four-fold increase in risk for the 
development of acral melanoma. Significantly, the acral sub-type has recently been shown 
to be associated with high levels of KIT expression. We additionally show that the presence 
of this KIT variant may lead to increased expression of KIT as evidenced via luciferase 
reporter constructs, which is likely due to decreased base pairing in the seed region of the 
miRNA:target duplex. Furthermore, this polymorphism is associated with increased KIT 
mRNA and protein levels in the majority of samples that harbor it. This work therefore 
identifies this KIT variant as a novel genetic marker for risk of acral melanoma, and suggests 
a mechanism through KIT mis-regulation.
Recent work by several groups presents a convincing argument for a significant oncogenic 
role for the KIT oncogene in at least some sub-classes of melanoma, renewing interest in 
KIT as a possible therapeutic target in these types, and highlighting the potential of KIT 
mutations to serve as biomarkers for melanoma risk. Multiple studies have found increased 
KIT expression in acral tumors lacking KIT amplifications or mutations (Curtin et al., 2006; 
Smalley et al., 2008), suggesting other forms of KIT mis-regulation. KIT is critical for the 
survival, proliferation and migration of melanocytes and precursor cells, and a mouse model 
of forced expression of constitutively active KIT in melanocytes exhibited increased 
migration of these cells (Alexeev & Yoon, 2006). These properties combined with its known 
oncogenic capabilities in other tissues highlight KIT as a candidate for a role in the 
development and pathogenesis of melanoma. However, work showing that KIT expression 
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declined rather than increased in melanomas relative to primary melanocytes (Funasaka et 
al., 1992; Lassam & Bickford, 1992; Natali et al., 1992), and that exogenous expression of 
KIT in some KIT-negative melanomas, or the addition of the KIT ligand to KIT positive 
melanoma cells, could induce apoptosis (Huang et al., 1998; Huang et al., 1996; Zakut et al., 
1993), runs contrary to this hypothesis. One study further showed that KIT is a target of the 
miRNA miR-221 and that expression of this miRNA increases over the progression of 
melanoma subsequent to silencing of its repressor PZLF, leading to down-regulation of KIT 
expression (Felicetti et al., 2008; Igoucheva & Alexeev, 2009).
However, given the robust oncogenic role of KIT in other cancers, combined with the 
genetic and histological complexity and diversity of melanoma as a cancer class, it is 
possible that KIT plays a transforming or pro-proliferative role in particular subtypes of 
melanoma, or at particular points in the transformation process, progression, migration or 
metastasis of the disease. Ours and other recent data support this hypothesis. KIT positivity 
has been shown in some sub-classes of melanoma, in the presence and absence of 
amplifications and activating mutations of KIT, particularly in the acral and mucosal 
subtypes (Curtin et al., 2006; Smalley et al., 2009b). In one report, KIT expression was 
found in melanomas that lack the activating V600E BRAF mutation (Curtin et al., 2006), the 
most common oncogenic mutation identified in melanomas, found in 42% of tumors (see 
COSMIC Database, Wellcome Sanger Trust), although this is not the case in our cohort of 
melanoma where KIT expression did not correlate with BRAF mutation status (Halaban, 
unpublished). However, of the 11 samples in our study harboring the KIT variant that were 
typed, only two (18%) carried BRAF mutations. Interestingly, one study described a group 
of KIT and cyclin-dependant kinase 4 (CDK4) positive melanomas with high levels of 
activated phospho-KIT that did not carry KIT mutations, and showed no evidence of a 
SCF/KIT autocrine loop, and yet exhibit high levels of activated phospho-KIT (Smalley et 
al., 2008). The authors suggest that signaling activity may have arisen from high KIT 
expression levels leading to spontaneous dimerization and activation of this receptor. 
Similarily, when we examined KIT phosphorylation status in wild-type samples and samples 
harboring the KIT variant, samples harboring the variant allele were phosphorylated more 
often and to a greater degree than wild-type samples (p=0.028) (Supplementary Fig. 1). We 
therefore speculate that the high expression of the protein within these cells due to 
repression inhibition in the presence of the variant allele may be sufficient to promote 
autoactivation of KIT, however further work is required to investigate this hypothesis.
Another study presented compelling evidence of a requirement for a specific epigenetic 
environment for KIT-dependent transformation, demonstrating that in some melanomas KIT 
cooperates with a hypoxia-inducible factor (HIF-1α) to activate the downstream 
Ras/Raf/Mek/Erk pathway, and that in the absence of hypoxia or exogenous expression of 
this factor, KIT was unable to induce transformation of melanocytes (Monsel et al., 2009). 
These authors speculate that this could contribute to the apparent tissue specificity of KIT-
driven melanomas, for example if hypoxic conditions exist in the extremities of the hands 
and feet where KIT-associated acral melanomas can occur. Of particular note, many 
melanomas expressing high levels of KIT have shown considerable response to the KIT 
inhibitor Imatinib both in cell-culture and xenograft models (Smalley et al., 2008). Two 
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patients presenting with metastatic melanoma exhibiting strong KIT expression showed 
significant response to treatment with Imatinib (Hodi et al., 2008; Lutzky et al., 2008). 
Phase II trials are currently underway for Imatinib treatment of patients with activating KIT 
mutations (Smalley et al., 2009b).
Our new work identifies a novel genetic marker for risk of acral melanoma, and presents a 
mechanism via mis-regulation of the KIT oncogene. Screening for the presence of this KIT 
variant may aid in early identification of at-risk patients, and may also be useful in 
predicting patients with enhanced response to treatment with RTK inhibitors, a hypothesis 
that warrants testing.
Materials and Methods
Sample populations
Tumor and case-control samples were from patients with a diagnosis of melanoma and from 
healthy individuals, respectively (Supplementary Table), and were collected with patients’ 
signed informed consent according to a protocol approved by the Yale University Human 
Investigation Committee. Tissue was collected from 70 melanoma patients and 94 controls. 
To determine the worldwide frequency of the KIT variant alleles, 2,765 individuals were 
genotyped from a global sample of 58 populations. According to population ancestry and 
geographic locations, these 58 populations are categorized into 9 groups: African, Southwest 
Asian, European, Siberian, Central Asian, Pacific Islander, East Asian, North American, and 
South American. Sample descriptions and samples sizes can be found in the Allele 
Frequency Database (ALFRED) by searching for the population names (Rajeevan et al., 
2005). DNA samples were extracted from lymphoblastoid cell lines established and/or 
grown in the Yale University laboratory of K. K. K. The methods of transformation, cell 
culture, and DNA purification have been described (Anderson & Gusella, 1984). All 
volunteers were apparently normal and otherwise healthy adult males or females and 
samples were collected after receipt of appropriate informed consent.
Sequencing of the KIT 3′UTR
DNA was isolated from frozen melanoma tumors from 25 patients using the DNeasy Blood 
and Tissue kit (Qiagen) according to manufacturer’s instructions. The entire 2158 nt KIT 
3′UTR was amplified using KOD Hot Start DNA polymerase (Novagen) according the 
manufacturer’s instructions (cycling conditions: 95 C for 2 minutes; then 35 cycles of: 95 C 
for 15 seconds, 57.8 C for 15 seconds, 72 C for 1 min 15 seconds; then 72 C for 10 minutes) 
using 50 nanograms (ng) of DNA, and primers flanking the region (forward primer (SG24): 
CCATCAGTTAGTTGTGATCTT, reverse primer (SG40) 
CCAGCTCATACATACTAAGCA). PCR products were purified using the QIAquick PCR 
Purification kit or 96 PCR Purification kit (Qiagen) according to manufacturer’s instructions 
and sequenced in three overlapping segments using 100 ng of purified DNA per reaction 
(forward primer segment 1 (SG24): CCATCAGTTAGTTGTGATCTT, reverse primer 
segment 1 (SG28): GGACATAATGCCAGGGTTGTA, forward primer segment 2 (SG27): 
GCTCTTCTGTGGACCACTGCAT, reverse primer segment 2 (SG38): 
GCATAGAACTCCAGTGCAA, forward primer segment 3 (SG39): 
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GCAAATGTGTACATGGCAGAGTT, and reverse primer segment 3 (SG40): 
CCAGCTCATACATACTAAGCA). Sequencing was carried out by the W.M. Keck 
Foundation Biotechnology Resource Laboratory at Yale University and sequences returned 
were viewed and analyzed using DNASTAR Lasergene SeqMan Pro DNA sequence 
analysis software.
SNP genotyping assays
For high-throughput genotyping of the rs17084733 locus, DNA was isolated from patient 
tumor and control samples as above, and was analyzed using a Taqman PCR based SNP 
assay specific for rs17084733 (Assay #: C__34674348_10 Applied Biosystems, context 
sequence: AACTGTATATATTCCCAATAGCAAC[A/
G]TAGCTTCTACCATGAACAGAAAACA) according to manufacturer’s instructions. 
Reactions were performed in a 25 microliter (μl) volume with 12.5 μl of 2x Taqman 
Genotyping Master Mix (Applied Biosystems), 1.25 μl of 20x of the SNP assay probe 
mixture (above) and 25 ng of purified DNA. Initial testing of the assay was performed by 
genotyping the 25 previously sequenced patient DNA samples as control, resulting in 100% 
accuracy relative to sequencing results for this locus. Subsequent assays were performed 
with the following controls: one reaction with water replacing DNA as negative control, one 
pre-sequenced wild-type sample, and one pre-sequenced sample heterozygous for 
rs17084733. Reactions were run in 96 well plates on the Applied Biosystems 7900HT Fast 
Real-Time PCR System, cycling conditions: 1 cycle of 50 C for 2 minutes, 95 C for 10 
minutes; 40 cycles of 95 C for 15 seconds, 60 C for 1 minute. Genotypes were analyzed 
using the Applied Biosystems SDS genotyping software.
KIT 3′UTR reporter construct
A psiCHECK-2 (Promega) derivative containing the entire KIT 3′UTR (KIT wild-type) was 
generated as follows. The KIT 3′UTR was amplified from human genomic DNA isolated as 
above using primers that included an XhoI and a NotI restriction site at the 3′ and 5′ ends of 
the UTR respectively (3′ end primer (SG43b): 
AAAAAAAActcgagGCAGAATCAGTGTTTGGGTCA, 5′ end primer (SG44b): 
AAAAAAAAgcggccgcTTGATTTATATATGTACATTTTATTAG). This fragment was 
cloned into a TOPO vector using the TOPO TA Cloning Kit (Promega) as according to 
manufacturers instructions and then sub-cloned into the psiCHECK-2 vector using the XhoI 
and a NotI sites in the multiple cloning site downstream from the Renilla luciferase coding 
region. The mutant variant was generated in the TOPO clone using the site-directed 
mutagenesis system GeneTailor (Invitrogen) as according to manufacturer’s instructions 
using mutagenic primers specific for rs17084733 (forward mutagenesis primer (SG49b): 
ATTCCCAATAGCAACaTAGCTTCTACCAT, reverse mutagenesis primer (SG50b): 
GTTGCTATTGGGAATATATACAGTTGGAA) and subsequently sub-cloned into the 
psiCHECK-2 vector as above. Vectors were sequenced as above, using 600 ng DNA. 
Vectors with downstream miR-221 binding sites knocked out were generated in the TOPO 
clone using the site-directed mutagenesis system GeneTailor (Invitrogen) as according to 
manufacturer’s instructions using mutagenic primers to replace the seed with adenosine 
repeats (site 1: forward mutatgenesis primer (SG100): 
TTGGATTCTTAAAAAAAAGGAAATAAAGTATAGG, reverse mutagenesis primer 
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(SG105): AAGAATCCAAACTAAGATGGCAGTGTTTTCCCACTCC; site 2: forward 
mutatgenesis primer (SG102): GTAAATATTGAAAAAAAAAAATAATGTC, reverse 
mutatgenesis primer (SG103): TTCAATATTTACAAAAAAAGCCAC) and subsequently 
sub-cloned into the psiCHECK-2 vector as above. Vectors were sequenced as above, using 
600 ng DNA.
Cell culture and transfection
501 mel and YUSAC2 melanoma cells were cultured in OptiMEM (Gibco) supplemented 
with 5% fetal bovine serum and penicillin/streptomycin (Invitrogen). For reporter expression 
assays, the cells were seeded in 6-well plates at 105 cells per well, grown for 48 hours and 
transfected using DMRIEC transfection reagent (Invitrogen) according to manufacturer’s 
instructions. Cells were incubated with DMRIEC transfection reagent (6.25 μl) and plasmid 
DNA (250 ng) encoding either wild-type or mutant KIT reporter constructs in OptiMEM 
(Invitrogen, Carlsbad, CA) in a final volume of 0.5 milliliters (ml) per well for 5 hours. 
OptiMEM (0.5 ml) supplemented with 10% fetal bovine serum was then added to each well, 
cells were incubated for 48 hours and collected for luciferase assay. Reporter expression was 
measured using the Dual-Luciferase Reporter Assay (Promega) according to manufacturer’s 
instructions.
Western blotting
Normal melanocytes and melanoma cells were lysed in buffer (PBS, 1% NP40, 0.5% 
sodium deoxycholate, and 0.1% SDS) supplemented with a mixture of protease (Complete 
Boehringer Mannheim Corp., Roche Molecular Biochemicals, Indianapolis, IN) and 
phosphatase (100 mM NaF, 10 mM Na4P2O7, and 1 mM Na3VO4) inhibitors. Total cell 
extracts (8 μg protein/lane), measured by the Bio-Rad protein assay (Bio-Rad Laboratories, 
Hercules, CA), were fractionated in precast gels composed of 4–12% gradient 
polyacrylamide (NuPAGE Bis-Tris, Invitrogen, Carlsbad, CA) and Western blotted 
according to standard protocols using rabbit anti-c-KIT antibody (C-19 sc-168, Santa Cruz 
Biotechnologies, Inc, Santa Cruz, CA).
Microarrays
NimbleGen human whole genome expression microarrays (array 
2005-04-20_Human_60mer and array 2006-08-03_HG18_60mer) were probed to determine 
gene expression in melanoma cells isolated from different tumors as previously described 
(Halaban et al., 2009; Koga et al., 2009).
miRNA expression analysis
MiRNA levels were determined by low density TaqMan arrays (Applied Biosystems) 
according to the manufacturer’s instructions as described previously (Godshalk et al., 2008).
Statistical analysis
KIT variant frequency data were included in univariate logistic regression models to assess 
significance. Multivariate logistic regression models were also investigated and included the 
SNP frequencies plus gender, age and race. Significance of microarray data was assessed via 
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Student’s t-test. Significance of the phosphorylation data was assessed via the Wilcoxon 
rank sum test.
KIT phosphorylation
Lysates of melanoma cell strains were analyzed using the Proteome Profiler human 
phospho-RTK arrays (catalogue number ARY001 R&D Systems, Minneapolis, MN) 
according to the manufacturer’s instructions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. A genetic variant in a miR-221 binding site in the 3′UTR of KIT
A. Schematic of the KIT 3′ UTR: miR-221 complementary sites are indicated, variant 
rs17084733 designated by a star. Inset diagram of miR-221 binding at a complementary site 
in the wild-type KIT 3′ UTR on top, and with rs17084733 variant allele present on bottom. 
Wild-type common allele G (top), with variant allele A (bottom) exhibiting decreased 
basepairing in the seed region of the miRNA::target duplex. In both cases the miR-221 is the 
bottom strand of the duplex. B. The miR-221 complementary site is highly conserved in 
mammals. Data extracted from the UCSB Genome Browser. Regions of conservation are 
shaded, black bar across top indicates regions base-pairing with miR-221, arrow indicates 
rs17084733 locus.
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Figure 2. Allelic frequency of the rs17084733 variant allele in world populations
Frequency of the variant (A) allele at rs17084733 in 2,765 individuals representing 58 
groups from 9 populations around the world.
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Figure 3. Frequency of heterozygosity of the KIT variant in case control, melanoma, and 
melanoma subtypes
Frequencies of heterozygosity of the variant allele are shown for the Yale-New Haven 
Hospital patient case-control cohort: all melanoma samples, and divided into non-acral and 
acral groups. Samples exhibiting a statistically significant difference (p<0.05) relative to 
control group are indicated with an asterix. (p-values: all melanoma=0.02, non-acral=0.070, 
acral=0.02.)
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Figure 4. Expression of KIT as analyzed in two independent microarrays
Relative mRNA levels in wild-type melanomas and melanomas harboring the KIT variant 
analyzed in two microarray experiments indicate the presence of the KIT variant correlates 
with significantly increased levels of KIT mRNA.
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Figure 5. KIT expression at the protein level
Western blot analysis of wild-type (A) and melanomas heterozygous for the KIT variant 
allele (B). (C) A histogram showing that the percentage of samples with KIT positivity in 
melanomas harboring the variant is twice that of melanoma cells wild-type at this locus.
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Figure 6. Reporter assays demonstrate an increase in expression from a construct containing the 
KIT variant relative to a wild-type construct
A. Relative luciferase activity normalized to internal vector controls in 501 mel cells 
transfected with wild-type and variant containing KIT 3′UTR reporter constructs indicate a 
statistically significant 6.7-fold increase in reporter expression from the construct containing 
the KIT variant, providing evidence that this KIT variant may result in increased expression 
of KIT. B. Relative luciferase activity normalized to scrambled pre-miR control and internal 
vector controls in YUSAC2 cells cotransfected with wild-type and variant containing KIT 
3′UTR reporter constructs and miR-221 pre-miR also indicate a statistically significant 1.2-
fold increase in luciferase activity from the construct containing the KIT variant.
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